Skip to main content

Table 12 Plasma miRNA results in MD patients with vs. without presence of LGE

From: Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

miRNA plasma levelsa (/103) LGE-negative LGE-positive p value
N = 15 N = 48
-206 13.18 (3.69–43.72) 22.85 (4.56–74.83) 0.54
-144-5p 15.70 (0.00–159.39) 4.93 (0.00–191.57) 0.95
-146b 81.86 (32.74–162.66) 44.23 (0.00–177.79) 0.32
-15b 7.42 (0.00–21.10) 0.00 (0.00–19.01) 0.41
-195 10.50 (2.70–17.48) 8.19 (0.54–21.93) 0.75
-20b 46.56 (31.69–74.64) 65.45 (19.35–86.58) 0.58
-21 67.48 (5.74–106.23) 11.82 (0.00–115.78) 0.65
-221 0.00 (0.00–32.92) 0.00 (0.00–10.03) 0.66
-222 1288.92 (355.69–1728.72) 2303.59 (1102.54–6059.36) 0.035
-26a 165.39 (36.75–291.31) 345.01 (139.78–616.20) 0.030
-29a 0.00 (0.00–.09) 0.00 (0.00–0.00) 0.61
-29c 0.00 (0.00–2.14) 0.00 (0.00–.65) 0.89
-342 1906.24 (491.08–2603.63) 2668.49 (1512.77–5205.06) 0.07
-378a-3p 13.18 (0.00–155.98) 40.31 (8.05–301.61) 0.26
-378a-5p 16.99 (1.04–36.13) 41.23 (14.62–102.03) 0.026
-451 106.88 (64.56–273.40) 207.05 (100.16–340.80) 0.29
-93 23.85 (0.77–52.24) 27.17 (0.00–70.37) 0.89
  1. (a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 103 in order to increase readability
  2. Bold text indicates a significant p-value of <0.05